Holen Sie sich die Stockscreener-App
41.42
0.19%
-0.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$41.50
Offen:
$41.42
24-Stunden-Volumen:
950.31K
Relative Volume:
0.13
Marktkapitalisierung:
$48.31B
Einnahmen:
$17.53B
Nettoeinkommen (Verlust:
$1.58B
KGV:
30.78
EPS:
1.3457
Netto-Cashflow:
$444.18M
1W Leistung:
+0.78%
1M Leistung:
+7.50%
6M Leistung:
+32.50%
1J Leistung:
+111.00%
1-Tages-Spanne:
$41.25
$41.88
1-Wochen-Bereich:
$40.71
$41.87
52-Wochen-Spanne:
$18.82
$42.02
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Firmenname
Teva Pharmaceutical Industries Ltd Adr
Sektor
Telefon
972 (3) 914-8213
Adresse
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.42 | 48.31B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
19.64 | 62.76B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.14 | 44.61B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.42 | 32.82B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
540.70 | 23.19B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-01 | Eingeleitet | TD Cowen | Buy |
| 2026-09-23 | Eingeleitet | Oppenheimer | Outperform |
| 2026-09-09 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-12-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-05-28 | Eingeleitet | Truist | Buy |
| 2025-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Hochstufung | Argus | Hold → Buy |
| 2024-03-08 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-11-27 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-06 | Hochstufung | UBS | Sell → Neutral |
| 2023-05-25 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-06-14 | Fortgesetzt | UBS | Neutral |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Herabstufung | Argus | Buy → Hold |
| 2021-10-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Herabstufung | UBS | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Eingeleitet | Oppenheimer | Perform |
| 2020-08-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Fortgesetzt | Goldman | Neutral |
| 2020-06-01 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-24 | Fortgesetzt | Citigroup | Neutral |
| 2020-04-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-02-24 | Herabstufung | Edward Jones | Hold → Sell |
| 2019-11-12 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-07-05 | Hochstufung | Argus | Hold → Buy |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-06-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Herabstufung | UBS | Buy → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-07 | Fortgesetzt | UBS | Buy |
Alle ansehen
Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten
Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGR - GlobeNewswire Inc.
Corcept Looks To End Teva's Mifepristone Antitrust Case - Law360
Small Molecule Active Pharmaceutical Ingredient Market Insights: Demand Trends, Competitive Landscape & Industry Outlook - EIN News
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026 - Quiver Quantitative
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire Inc.
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. - MarketBeat
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Teva Wins FDA Approval For Schizophrenia Innovation - Healthcare Digital
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs - Yahoo Finance
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Pretax income of Teva Pharmaceutical Industries Limited – BMV:TEVA1/N - TradingView
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo Finance
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Earnings Transcripts - GuruFocus
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Price, Trades & News - GuruFocus
Teva Pharmaceutical Industries Ltd. Advanced Charts | TEVA - Barron's
Teva Pharmaceutical Industries Ltd. Financials | TEVA - Barron's
Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza - Haaretz
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo! Finance Canada
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth InitiativesSlideshow (NYSE:TEVA) 2026-10-09 - Seeking Alpha
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Oppenheimer Adjusts Teva Pharmaceutical Industries PT to $52 From $50, Maintains Outperform Rating - Yahoo Finance
Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives - Fierce Pharma
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Teva Pharmaceutical Industries Ltd. Research & Ratings | TEVA1N - Barron's
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia - Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. Company & People | TEVA - Barron's
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price - Simply Wall Street
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround - The Motley Fool
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Short Interest Update - MarketBeat
Is Teva Pharmaceutical Industries (TEVA) Undervalued Following New Phase 3 Schizophrenia Data? - simplywall.st
Teva, Wyeth Show How Claimed Advances Shape Enablement - Law360
Teva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026 - quiverquant.com
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire Inc.
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire Inc.
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock - Moomoo
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - finance.yahoo.com
Oppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - Yahoo Finance
TEVA: Investment grade status enables accelerated innovation, robust launches, and renewed generics growth - TradingView
TEVA: Focus shifts to innovation, high-margin launches, and renewed growth in generics and biosimilars - TradingView
Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock - MarketBeat
Finanzdaten der Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MIGNONE ROBERTO | Director |
Sep 18 '26 |
Sale |
39.06 |
367,600 |
14,356,802 |
0 |
| Bridger Management, LLC (1) | Shareholder |
Sep 18 '26 |
Proposed Sale |
39.19 |
367,600 |
14,406,244 |
0 |
| Savage Brian | Officer |
Sep 18 '26 |
Proposed Sale |
38.85 |
7,028 |
273,062 |
0 |
| Savage Brian | Interim Chief Legal Officer |
Sep 18 '26 |
Sale |
38.85 |
7,342 |
285,215 |
8,500 |
| Satchi-Fainaro Ronit | Director |
Aug 21 '26 |
Sale |
37.25 |
415 |
15,459 |
111,986 |
| Weiss Amir | Chief Accounting Officer |
Aug 21 '26 |
Option Exercise |
19.61 |
2,500 |
49,025 |
15,571 |
| Weiss Amir | Chief Accounting Officer |
Aug 21 '26 |
Sale |
37.62 |
9,445 |
355,301 |
13,071 |
| Lippman Evan | EVP, Business Development |
Aug 17 '26 |
Sale |
36.57 |
18,600 |
680,291 |
25,591 |
| Lippman Evan | Officer |
Aug 17 '26 |
Proposed Sale |
36.57 |
18,600 |
680,291 |
0 |
| Zaks Tal Zvi | Director |
Aug 05 '26 |
Sale |
34.87 |
17 |
593 |
73,247 |
0.15%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):